ZLAB Zai Lab Ltd: Earnings per share for the last twelve months

Zai Lab Ltd (ZLAB) - corporate logo

Zai Lab Limited scales revenue by licensing foreign drugs in China, thereby minimizing R&D costs. The YoY (ttm) EPS percentage growth history visualizes the market valuation through earnings per share dynamics, where the value of 8.20 expresses the metric level. Efficient cross-border logistics reduce shortage risks, while the integration of oncology drugs into insurance systems accelerates the holding's expansion.

ZLAB: Zai Lab Net earnings per share (EPS TTM) 02/11/2024 - 11/10/2026

Zai Lab Ltd. - analytical breakdowns and key metrics (ZLAB)

- price and consensus price forecast:
Market Price zailaboratory.com|ZLAB - Price Target Chart
- company stock capitalization data:
Market Value Zai Lab Ltd|ZLAB - Enterprise Value
- balance sheet net asset value indicators:
Equity per Share Zai Lab|ZLAB - Book Capitalization|Market Capitalization to Book Value zailaboratory.com|ZLAB - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity Ratio Zai Lab Limited|ZLAB - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Zai Lab Corp|ZLAB - Company Total Debt|Debts to Book Capitalization Ratio Zai Lab Ltd|ZLAB - Company Long-Term Debts|Company Short-Term Debts Zai Lab|Interim Coverage Ratio zailaboratory.com
- earnings and valuation multiples information:
ZLAB - Net Income|Expected Net Income Zai Lab Limited|ZLAB - Price to Earnings Ratio|Future Price to Earnings Zai Lab Ltd|ZLAB - PEG Multiple|EV/EBITDA Multiple Zai Lab Ltd|ZLAB - Operating profit EBITDA|Earnings per share for the last twelve months Zai Lab|ZLAB - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months zailaboratory.com|ZLAB - Earnings per share growth in current year|Net earnings per share growth forecast for next year Zai Lab Limited
Fundamental valuation:zailaboratory.com
Finished products of Zai Lab Ltd.

Year-over-year EPS growth (TTM) measures the rate of change in net income per share over a rolling year, neutralizing seasonal distortions and demonstrating real efficiency in capital generation. By analyzing the historical annual dynamics of EPS TTM, an investor can see how the strategy of licensing Western drugs and the development of IT distribution at Zai Lab Limited (ZLAB) convert sales into margins without R&D costs, confirming the sustainability of the business value.

Competitor analysis for Zai Lab Limited

Net earnings per one share for the last twelve months lilly.com|AbbVie (ABBV) - Earnings per share for the last twelve months|AZN (AstraZeneca Plc) - Earnings per share for the last twelve months|NVS (Novartis Inc.) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months MRK (MSD)|Net earnings per share (EPS TTM) NVO|Net earnings per share for the last four quarters amgen.com|Earnings per share for the last twelve months Pfizer PFE|SNY: Earnings per share for the last 12 months|BMS - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year GSK plc (GSK)|TAK (Takeda Pharmaceutical) - Net earnings per share for the last 12 months|Earnings per one share for the last 12 months TEVA (Teva)|RDY (Dr. Reddy's) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Viatris Inc|Net earnings per share (EPS TTM) ROIV|Net earnings per share for the last four quarters Bausch Health Corp|Cosmos Health Inc. - Net earnings per share for the last 12 months